The PD-1 Resistant Head and Neck Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the PD-1 Resistant Head and Neck Cancer market dynamics.
DelveInsight’s “PD-1 Resistant Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of Psoriatic Arthritis, historical and forecasted epidemiology as well as the PD-1 Resistant Head and Neck Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key highlights of the PD-1 Resistant Head and Neck Cancer Market Report
Download Sample Report- https://www.delveinsight.com/sample-request/pd-1-resistant-head-and-neck-cancer-hnc-market
Key benefits of the PD-1 Resistant Head and Neck Cancer Market report:
PD-1 Resistant Head and Neck Cancer Overview
Head and Neck Cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinoma of Head and Neck Cancer. The symptoms of Head and Neck Cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Symptoms may vary depending upon the site of cancer.
PD-1 Resistant Head and Neck Cancer Symptoms
The symptoms of Head and Neck Cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Symptoms may vary depending upon the site of cancer.
PD-1 Resistant Head and Neck Cancer Treatment
For those able to receive treatment for metastatic spread, treatment again consists mainly of systemic therapies: cytotoxic chemotherapy, cytotoxic chemotherapy combined with cetuximab, or immunotherapy. For those who have a significant burden of symptoms but are still able to receive systemic therapy, single agent rather than combination therapy is recommended.
PD-1 Resistant Head and Neck Cancer Emerging Drugs
Monalizumab (IPH2201): AstraZeneca/Innate Pharma
Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T-cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently overexpressed on cancer cells of many solid tumors and hematological malignancies.
Buparlisib: Adlai Nortye Biopharma
Buparlisib is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and is active in both hematologic malignancies and solid tumors. Buparlisib significantly inhibited tumor growth in the animal model and showed a dose-response trend in anti-PD-1 refractory tumor-bearing mice. The dose range of buparlisib was consistent with previous preclinical studies conducted with BKM120 (Buparlisib, AN2025) by Novartis.
PD-1 Resistant Head and Neck Cancer Market Companies
PD-1 Resistant Head and Neck Cancer Therapies
Request Sample Report- https://www.delveinsight.com/sample-request/pd-1-resistant-head-and-neck-cancer-hnc-market
Table of Content
1. Key Insights
2. Executive Summary of PD-1 Resistant Head and Neck Cancer
3. Competitive Intelligence Analysis for PD-1 Resistant Head and Neck Cancer
4. PD-1 Resistant Head and Neck Cancer Market Overview at a Glance
5. PD-1 Resistant Head and Neck Cancer Disease Background and Overview
6. Patient Journey
7. PD-1 Resistant Head and Neck Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. PD-1 Resistant Head and Neck Cancer Unmet Needs
10. Key Endpoints of PD-1 Resistant Head and Neck Cancer Treatment
11. PD-1 Resistant Head and Neck Cancer Marketed Products
12. PD-1 Resistant Head and Neck Cancer Emerging Therapies
13. PD-1 Resistant Head and Neck Cancer (AUD): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: PD-1 Resistant Head and Neck Cancer Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. PD-1 Resistant Head and Neck Cancer Market Drivers
19. PD-1 Resistant Head and Neck Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
PD-1 Resistant Head and Neck Cancer Market Report Highlights
Why should you buy this report?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: YashEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/